Dental alloplastic bone substitutes currently available in Korea
10.5125/jkaoms.2019.45.2.51
- Author:
Jeong Kui KU
1
;
Inseok HONG
;
Bu Kyu LEE
;
Pil Young YUN
;
Jeong Keun LEE
Author Information
1. Department of Oral and Maxillofacial Surgery, Asan Medical Center, Seoul, Korea.
- Publication Type:Review
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2019;45(2):51-67
- CountryRepublic of Korea
- Language:English
-
Abstract:
As dental implant surgery and bone grafts were widely operated in Korean dentist, many bone substitutes are commercially available, currently. For commercially used in Korea, all bone substitutes are firstly evaluated by the Ministry of Health and Welfare (MOHW) for safety and efficacy of the product. After being priced, classified, and registration by the Health Insurance Review and Assessment Service (HIRA), the post-application management is obligatory for the manufacturer (or representative importer) to receive a certificate of Good Manufacturing Practice by Ministry of Food and Drug Safety. Currently, bone substitutes are broadly classified into C group (bone union and fracture fixation), T group (human tissue), L group (general and dental material) and non-insurance material group in MOHW notification No. 2018-248. Among them, bone substitutes classified as dental materials (L7) are divided as xenograft and alloplastic bone graft. The purpose of this paper is to analyze alloplastic bone substitutes of 37 products in MOHW notification No. 2018-248 and to evaluate the reference level based on the ISI Web of Knowledge, PubMed, EMBASE (1980–2019), Cochrane Database, and Google Scholar using the criteria of registered or trademarked product name.
